{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:42:19Z","timestamp":1773283339705,"version":"3.50.1"},"reference-count":16,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2010]]},"abstract":"Our aim was to determine the prevalence of multidrug resistance of <i>Acinetobacter baumannii <\/i>and other pathogens at a tertiary-care teaching hospital in Mexico over a 3-year period. Clinical isolates of <i>A. baumannii <\/i>(n = 550), <i>Pseudomonas aeruginosa<\/i> (n = 250), some Enterobacteriaceae species (n = 500) and <i>Staphylococcus aureus<\/i> (n = 250) collected over a 3-year period were included. Susceptibility tests were performed by the broth microdilution method. 74% of <i>A. baumannii<\/i>, 40% of <i>Escherichia coli<\/i>, 34% of <i>P. aeruginosa,<\/i> 22% of <i>Klebsiella pneumoniae<\/i>, 9% of <i>Enterobacter cloacae<\/i>, and 7% of <i>Serratia <\/i>sp. were multidrug resistant. 59% of <i>A. baumannii<\/i> clinical isolates were meropenem-resistant. <i>A. baumannii<\/i> isolates from the lower respiratory tract were the most susceptible, followed by urine clinical isolates. Species from Enterobacteriaceae showed susceptibility rates higher than 90% to meropenem and tigecycline and <i>Serratia <\/i>sp. showed the highest susceptibility to the drugs evaluated. For <i>P. aeruginosa<\/i>, the most potent drug was levofloxacin, followed by meropenem and piperacillin-tazobactam. With regard to <i>S. aureus<\/i>, 96% of the isolates were susceptible to vancomycin, followed by tigecycline and minocycline (91% of strains susceptible). The high multidrug resistance observed underscores the need for surveillance of bacterial drug resistance.<\/jats:p>","DOI":"10.1159\/000319903","type":"journal-article","created":{"date-parts":[[2010,8,9]],"date-time":"2010-08-09T06:56:32Z","timestamp":1281336992000},"page":"275-279","source":"Crossref","is-referenced-by-count":35,"title":["Prevalence of Multidrug-Resistant Bacteria at a Tertiary-Care Teaching Hospital in Mexico: Special Focus on <i>Acinetobacter baumannii<\/i>"],"prefix":"10.1159","volume":"56","author":[{"given":"Elvira","family":"Garza-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Mart\u00edn","family":"Llaca-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Bosques-Padilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria M.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2010,8,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ijantimicag.2008.06.016"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199808203390806"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186%2Fcc6820"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkn241"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1128%2FCMR.00058-07"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMra070741"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.01464-06"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.diagmicrobio.2004.02.003"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159%2F000086574"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1086%2F518842"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1086%2F320183"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159%2F000220245"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkm310"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159%2F000167788"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159%2F000085615"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016%2FS0732-8893%2802%2900371-1"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/319903","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/319903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:46:17Z","timestamp":1745437577000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000319903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2010,8,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000319903","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}